New hope for ALS patients: experimental drug NX210c enters phase 2 trial
Disease control
Ongoing
This study tests an experimental drug called NX210c in 80 adults with ALS, a progressive nerve disease. Participants receive multiple intravenous infusions of the drug or a placebo to see if it can slow the disease by measuring nerve damage markers in blood and spinal fluid. The …
Phase: PHASE2 • Sponsor: Axoltis Pharma • Aim: Disease control
Last updated May 26, 2026 12:05 UTC